Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;62(6):650-656.
doi: 10.1111/head.14319. Epub 2022 May 11.

Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management

Affiliations
Review

Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management

Pedro Augusto Sampaio Rocha-Filho. Headache. 2022 Jun.

Abstract

Objective: To review data regarding the epidemiology, pathophysiology, characteristics, and management of COVID-19-associated headache. The persistence of headache after the acute phase of COVID-19 was also reviewed.

Background: Headache is a frequent symptom of COVID-19, and understanding its management is important for health-care professionals involved in treating the disease.

Method: This is a narrative review. A literature review was conducted in the PubMed database with the following terms: "headache" and "COVID-19." All articles written in English that were considered relevant were included.

Results: Half of the patients who have COVID-19 present with headache, which occurs more frequently in younger patients; in those with previous primary headache or with previous migraine; and in those who have concomitantly presented with anosmia, ageusia, and myalgia. The headache usually begins early in the symptomatic phase, is bilateral, moderate to severe, and has a similar pattern to tension-type headache. All studies found the migraine pattern and the tension-type headache pattern to be frequent patterns. The possible pathophysiological mechanisms include direct viral injury, the inflammatory process, hypoxemia, coagulopathy, and endothelial involvement. Common analgesics and nonsteroidal anti-inflammatory drugs are the most commonly used drugs for headache in the acute phase of COVID-19. The headache may persist beyond the acute phase, and in such cases, there is an improvement over time. However, not all patients' headaches improve. It seems to be a greater proportion of patients whose headache improves in the first 3 months after the acute phase of the disease than after this period. COVID-19 may trigger new daily persistent headache.

Conclusions: Headache is a clinically significant symptom of COVID-19. Although its characteristics in the acute phase of the disease are already well known, there is a need for studies on its management and persistence.

Keywords: COVID-19; disease management; headache; headache disorders, secondary; physiopathology; post-acute COVID-19 syndrome.

PubMed Disclaimer

Conflict of interest statement

The author reports no relevant conflicts of interest.

References

    1. Karadaş Ö, Öztürk B, Sonkaya AR. A prospective clinical study of detailed neurological manifestations in patients with COVID‐19. Neurol Sci. 2020;41(8):1991‐1995. - PMC - PubMed
    1. Liguori C, Pierantozzi M, Spanetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS‐CoV2 infection. Brain Behav Immun. 2020;88:11‐16. - PMC - PubMed
    1. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients. Ann Clin Transl Neurol. 2020;7(11):2221‐2230. - PMC - PubMed
    1. Romero‐Sánchez CM, Díaz‐Maroto I, Fernández‐Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID‐19: the ALBACOVID registry. Neurology. 2020;95(8):e1060‐e1070. - PMC - PubMed
    1. Pinna P, Grewal P, Hall JP, et al. Neurological manifestations and COVID‐19: experiences from a tertiary care center at the Frontline. J Neurol Sci. 2020;415:116969. - PMC - PubMed